Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Gland Pharma Limited (NSE: GLAND), ISIN INE068V01023 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
GLAND last traded at ₹3316.20 (+5.85%), with a 52-week range of ₹1573.60 to ₹3374.00 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 45.75%, FIIs 10.36%, DIIs 33.21%, mutual funds 29.52%.
EquiSense Score (ECS): 67/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.